RecruitingPhase 1 / Phase 2NCT06541262
47
studies recruiting now
as of 7 Sept 2026
377
studies registered in total
as of 7 Sept 2026
4
countries with a recruiting site
as of 7 Sept 2026
7 Apr 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1NCT05857969
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
RecruitingPhase 3NCT07466316
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
RecruitingPhase 3NCT05304585
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
RecruitingNot applicableNCT07514819
Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 47 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Rhabdomyosarcoma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Rhabdomyosarcoma
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
12 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Dactinomycin (Cosmegen)
Phase 3Cyclophosphamide (Cyclophosphamide)
Phase 3Vincristine Sulfate (Leurocristine sulfate)
Phase 2Vinorelbine
Phase 2Indinavir Sulfate (Crixivan)
Phase 2Vincristine
Phase 1/2Dasatinib Anhydrous (Dasatinib accord)
Phase 1/2Ganitumab
+ 4 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).